Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

Experimental Neurology

Volumn 288, Issue , 2017, Pages 176-186

  Tamargo, Ian A ^a   Bader, Miaad ^b   Li, Yazhou ^a   Yu, Seong Jin ^c   Wang, Yun ^c   Talbot, Konrad ^d   DiMarchi, Richard D ^e   Pick, Chaim G ^b   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Incretin; Incretin mimetic; Neurodegeneration; Traumatic brain injury

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR; GLUTAMIC ACID; HORMONE RECEPTOR; HYDROGEN PEROXIDE; INCRETIN; NEUROPROTECTIVE AGENT; TWINCRETIN; UNCLASSIFIED DRUG; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; HUMAN; HUMAN CELL; MALE; MOUSE; MOUSE MODEL; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY; VISUAL MEMORY; AGONISTS; ANIMAL; BODY TEMPERATURE; BRAIN INJURIES, TRAUMATIC; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MAMMALIAN EMBRYO; MAZE TEST; MEMORY DISORDERS; METABOLISM; NEUROBLASTOMA; PATHOLOGY; RECOGNITION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; BODY TEMPERATURE; BRAIN INJURIES, TRAUMATIC; CELL LINE, TUMOR; CELLS, CULTURED; CREB-BINDING PROTEIN; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, GASTROINTESTINAL HORMONE; RECOGNITION (PSYCHOLOGY); SIGNAL TRANSDUCTION;

EID: 85002078883     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.11.005     Document Type: Article

References (92)

1. Acosta, S.A., et al. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J. Cell. Physiol. 230 (2015), 1024–1032.
2. Alcalay, R.N., et al. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 361 (2004), 12–131.
3. Al-Sabah, S., Al-Fulaij, M., Ahmed, H.A., Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur. J. Pharmacol. 741 (2014), 311–315.
4. Alvarez, E., et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92 (2005), 798–806.
5. Anderberg, R.H., et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65 (2016), 54–66.
6. Athauda, D., Foltynie, T., The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov. Today 21 (2016), 802–818.
7. Baratz, R., et al. Tumor necrosis factor-α synthesis inhibitor, 3,6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J. Neurochem. 118 (2011), 1032–1042.
8. Barkhoudarian, G., Hovda, D.A., Giza, C.C., The molecular pathophysiology of concussive brain injury. Clin. Sports Med. 30:33–48 (2011), vii–viii.
9. Barkhoudarian, G., Hovda, D.A., Giza, C.C., The molecular pathophysiology of concussive brain injury - an update. Phys. Med. Rehabil. Clin. N. Am. 27 (2016), 373–393.
10. Barnes, D.E., et al. Traumatic brain injury and risk of dementia in older veterans. Neurology 83 (2014), 312–319.
11. Bassil, F., et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. Prog. Neurobiol. 118 (2014), 1–18.
12. Beers, S.R., Cognitive effects of mild head injury in children and adolescents. Neuropsychol. Rev. 3 (1992), 281–320.
13. Belzung, C., Griebel, G., Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125 (2001), 141–149.
14. Bertilsson, G., et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338.
15. Briyal, S., Gulati, K., Gulati, A., Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res. 1427 (2012), 23–34.
16. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
17. Cao, L., et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport, 2016.
18. Cassidy, J.D., et al., Injury, W.H.O.C.C.T.F.O.M.T.B., Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO collaborating centre task force on mild traumatic brain injury. J. Rehabil. Med., 2004, 28–60.
19. Chen, Y., et al. The involvement of secondary neuronal damage in the development of neuropsychiatric disorders following brain insults. Front. Neurol., 5, 2014, 22.
20. Chuah, Y.M., Maybery, M.T., Fox, A.M., The long term effects of mild head injury on short term memory for visual form, spatial location and their conjunction in a well-functioning university students. Brain Cogn. 56 (2004), 304–312.
21. Ciccarone, V., et al. Phenotypic diversification in human neuroblastoma cells: Expression of distinct neural crest lineages. Cancer Res. 49 (1989), 219–225.
22. Crane, P.K., et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 73 (2016), 1062–1069.
23. Dachir, S., et al. Inosine improves functional recovery after experimental traumatic brain injury. Brain Res. 1555 (2014), 78–88.
24. Dellu, F., Mayo, W., Cherkaoui, J., Le Moal, M., Simon, H., A two-trial memory task with automated recording: study in young and aged rats. Brain Res. 588 (1992), 132–139.
25. De Toro-Martin, J., et al. Predominant role of GIP in the development of a metabolic syndrome-like phenotype in female Wistar rats submitted to forced catch-up growth. Endocrinology 155 (2014), 3769–3780.
26. Deselms, H., et al. Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. J. Neurosci. Methods, 2016 (Epub ahead of print).
27. Dix, S.L., Aggleton, J.P., Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav. Brain Res. 99 (1999), 191–200.
28. DHEW Publication (NIH) 85-23, Revised, https://www.ncbi.nlm.nih.gov/books/NBK54050/, 1995.
29. Doulames, V.M., et al. Social interaction attenuates the extent of secondary neuronal damage following closed head injury in mice. Front. Behav. Neurosci., 9, 2015, 275.
30. Duarte, A.I., et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim. Biophys. Acta 1832 (2013), 527–541.
31. Eakin, K., et al. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One, 8, 2013, e82016.
32. Edut, S., Rubovitch, V., Schreiber, S., Pick, C.G., The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI). Psychopharmacology (Berl). 214 (2011), 877–889.
33. Faul, M., et al. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002–2006. Ctr. Dis. Control Prev., 2010 (National Center for Injury Prevention and Control).
34. Finan, B., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013, 209ra151.
35. Gardner, R.C., et al. Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurol 71 (2014), 1490–1497.
36. Gardner, R.C., et al. Traumatic brain injury in later life increases risk for Parkinson disease. Ann. Neurol. 77 (2015), 987–995.
37. Gault, V.A., et al. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290 (2002), 1420–1426.
38. Gault, V.A., et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46 (2003), 222–230.
39. Greig, N.H., et al. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement. 10 (2014), S62–S75.
40. Greve, M.W., Zink, B.J., Pathophysiology of traumatic brain injury. Mt Sinai J. Med. 76 (2009), 97–104.
41. Han, L., et al. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Neuroreport 27 (2016), 23–32.
42. Hansen, H.H., et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease. J. Alzheimers Dis. 46 (2015), 877–888.
43. Harkavyi, A., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br. J. Pharmacol. 159 (2010), 495–501.
44. Holscher, C., Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221 (2014), T31–T41.
45. Hutson, C.B., et al. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma. 28 (2011), 1783–1801.
46. Impellizzeri, D., et al. Traumatic brain injury leads to development of Parkinson's disease related pathology in mice. Front. Neurosci., 10, 2016, 458.
47. Isacson, R., et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650 (2011), 249–255.
48. Ji, C., et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634 (2016), 1–11.
49. Kastin, A.J., Akerstrom, V., Pan, W., Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18 (2002), 7–14.
50. Kim, S.J., et al. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol. Cell. Biol. 28 (2008), 1644–1656.
51. Konrad, C., et al. Long-term cognitive and emotional consequences of mild traumatic brain injury. Psychol. Med. 2010 (2010), 1–15.
52. LaPlaca, M.C., et al. CNS injury biomechanics and experimental models. Prog. Brain Res. 161 (2007), 13–26.
53. Li, Y., et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 1285–1290.
54. Li, Y., et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19 (2010), 1205–1219.
55. Li, Y., et al. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113 (2010), 1621–1631.
56. Li, Y., et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One, 7, 2012, e32008.
57. Li, Y., et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 135 (2015), 1203–1217.
58. Liu, W., et al. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 303 (2015), 42–50.
59. Liu, W., et al. Neuroprotective effects of geniposide on Alzheimer's disease pathology. Rev. Neurosci. 26 (2015), 371–383.
60. Lotharius, J., Dugan, L.L., O'Malley, K.L., Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19 (1999), 1284–1293.
61. Martin, B., et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58 (2009), 318–328.
62. McClean, P.L., et al. The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease. Regul. Pept., 164, 2010, 40.
63. Mehta, A., et al. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 698 (2013), 6–18.
64. Melo, A., et al. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxidative Med. Cell. Longev., 2011, 2011, 467180.
65. Morganti-Kossmann, M.C., et al. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 8 (2002), 101–105.
66. Nyberg, J., et al. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J. Neurosci. Res. 85 (2007), 2099–2119.
67. Orman, J.A.L., Kraus, J.F., Zaloshnja, E., M., S.J., W., M.T., C., Y.S., Epidemiology. Textbook of Traumatic Brain Injury, 2011, American Psychiatric Pub, Washington, DC, 3–22.
68. Perry, T., Greig, N.H., The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol. Sci. 24 (2003), 377–383.
69. Perry, T., et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72 (2003), 603–612.
70. Perry, T., et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203 (2007), 293–301.
71. Rachmany, L., et al. Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-α. PLoS One, 8, 2013, e79837.
72. Rachmany, L., et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr.) 35 (2013), 1621–1636.
73. Sakamoto, K., Karelina, K., Obrietan, K., CREB: a multifaceted regulator of neuronal plasticity and protection. J. Neurochem. 116 (2011), 1–9.
74. Salcedo, I., et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 166 (2012), 1586–1599.
75. Schiehser, D.M., et al. Cognitive functioning in individuals with Parkinson's disease and traumatic brain injury: a longitudinal study. Parkinsonism Relat. Disord. 30 (2016), 58–61.
76. Schmidt, O.I., et al. Closed head injury - an inflammatory disease?. Brain Res. Brain Res. Rev. 48 (2005), 388–399.
77. Shahaduzzaman, M., Acosta, S., Bickford, P.C., Borlongan, C.V., α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury. Med. Hypotheses 81 (2013), 675–680.
78. Shao, W., et al. GLP-1(28-36) improves beta-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/beta-catenin signaling in beta-cells in vitro. Am. J. Physiol. Endocrinol. Metab. 304 (2013), E1263–E1272.
79. Skelton, R.W., et al. Humans with traumatic brain injuries show place-learning deficits in computer-generated virtual space. J. Clin. Exp. Neuropsychol. 22 (2000), 157–175.
80. Sparre-Ulrich, A.H., et al. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br. J. Pharmacol. 173 (2016), 27–38.
81. Thurman, D.J., et al. Traumatic brain injury in the United States: a public health perspective. J. Head Trauma Rehabil. 14 (1999), 602–615.
82. Tweedie, D., Apoptotic and behavioral sequelae of mild brain trauma in mice. J. Neurosci. Res. 85 (2007), 805–815.
83. Tweedie, D., et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp. Neurol. 239 (2013), 170–182.
84. Tweedie, D., et al. Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiol. Dis. 54 (2013), 1–11.
85. Tweedie, D., et al. Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. Alzheimers Dement. 12 (2016), 34–48.
86. Walker, K.R., Tesco, G., Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front. Aging Neurosci., 5, 2013, 29.
87. Wu, T., Rayner, C.K., Horowitz, M., Incretins. Handb. Exp. Pharmacol. 233 (2016), 137–171.
88. Yu, Y.W., et al. Glucose-dependent insulinotropic polypeptide ameliorates mild traumatic brain injury-induced cognitive and sensorimotor deficits and neuroinflammation in rats. J Neurotrauma, 2016.
89. Zaloshnja, E., et al. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J. Head Trauma Rehabil. 23 (2008), 394–400.
90. Zohar, O., et al. Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience 118 (2003), 949–955.
91. Zohar, O., et al. Behavioral consequences of minimal traumatic brain injury in mice. Acta Neurobiol. Exp. (Wars) 71 (2011), 36–45.
92. Bales, J.W., et al. Targeting dopamine in acute traumatic brain injury. Open Drug Delivery J. 2 (2010), 119–128.